Seroprevalence of varicella-zoster virus antibody and immunogenicity of live attenuated varicella vaccine in healthcare workers in Taiwan

被引:5
|
作者
Chong, Chen Hui [1 ]
Liu, Chun-Eng [1 ,2 ]
Leong, Yin-Yee [3 ]
Liao, Siang-Ying [2 ]
Lai, Huei-Wen [2 ]
Lee, Yu-Lin [1 ,2 ,4 ]
机构
[1] Changhua Christian Hosp, Dept Infect Dis, Changhua, Taiwan
[2] Changhua Christian Hosp, Dept Infect Control, Changhua, Taiwan
[3] Feng Chia Univ, Dept Risk Management & Insurance, Taichung, Taiwan
[4] Changhua Christian Hosp, Dept Infect Dis, 135,Nanxiao St, Changhua 500, Changhua County, Taiwan
关键词
Vaccination; Seroresponse; Seroconversion; Seroreversion; Nosocomial infection; HERPES-ZOSTER; IMMUNITY; OBESITY; EPIDEMIOLOGY; CHICKENPOX; INFECTION; OUTBREAK; TITERS; ADULTS;
D O I
10.1016/j.jmii.2022.09.005
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background: Healthcare workers (HCWs) without evidence of immunity to varicella-zoster virus (VZV) are recommended to undergo varicella vaccination. Immunogenicity of live attenuated varicella vaccine has rarely been investigated among HCWs in Taiwan. Methods: Anti-VZV immunoglobulin G (IgG) titer was checked for all HCWs at Changhua Christian Hospital from 2011 to 2017. One-dose and two-dose (separated by 4-8 weeks) vaccines were administered to HCWs with equivocal and negative anti-varicella IgG results, respectively. Follow-up anti-VZV IgG was determined at least 4 weeks after completion of vaccination. Factors associated with seroconversion to varicella vaccination were analyzed. Results: Among 2406 included HCWs, the anti-VZV IgG serostatus was tested positive, equivocal and negative in 1924 (79.9%), 117 (4.9%) and 365 (15.2%), respectively. The seroprevalence had decreased from 88.0% (235/267) in 2011 to 72.2% (270/374) in 2017 (p for trend <0.05). A total of 67.8% (327/482) HCWs completed scheduled vaccination and serological follow-up. The seroconversion rates for HCWs with baseline equivocal and negative anti-VZV IgG results were 100% (80/80) and 79.4% (196/247) after one- and two-dose vaccination, respectively. In multivariate analysis, obesity (adjusted odds ratio, 0.308; 95% confidence interval [CI], 0.11-0.94, p Z 0.039) was the only factor statistically significantly associated with seroconversion to vaccination. Conclusion: Decreasing trends of seroprevalence of VZV were observed among HCWs from 2011 to 2017. HCWs who were obese were less likely to respond to varicella vaccination.
引用
收藏
页码:274 / 281
页数:8
相关论文
共 50 条
  • [31] IMMUNOGENICITY IN MICE OF VARICELLA-ZOSTER VIRUS GLYCOPROTEIN-I EXPRESSED BY A VACCINIA VIRUS VARICELLA-ZOSTER VIRUS RECOMBINANT
    LUDVIKOVA, V
    KUNKE, D
    HAMSIKOVA, E
    KUTINOVA, L
    VONKA, V
    JOURNAL OF GENERAL VIROLOGY, 1991, 72 : 1445 - 1449
  • [32] Outbreak of varicella-zoster virus infection among Thai Healthcare workers
    Apisarnthanarak, Anucha
    Kitphati, Rungrueng
    Tawatsupha, Pranee
    Thongphubeth, Kanokporn
    Apisarnthanarak, Piyaporn
    Mundy, Linda M.
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2007, 28 (04): : 430 - 434
  • [33] Persistence of immunity to varicella-zoster virus after vaccination of healthcare workers
    Saiman, L
    LaRussa, P
    Steinberg, SP
    Zhou, J
    Baron, K
    Whittier, S
    Della-Latta, P
    Gershon, AA
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2001, 22 (05): : 279 - 283
  • [34] The live attenuated varicella-zoster virus vaccine vOka: Molecular and cellular biology of its skin attenuation
    Tommasi, Cristina
    Drousioti, Andriani
    Breuer, Judith
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2025, 21 (01)
  • [35] Varicella-zoster virus seroprevalence in children and adolescents in the prevaricella vaccine era, Germany
    Wiese-Posselt, Miriam
    Siedler, Anette
    Mankertz, Annette
    Sauerbrei, Andreas
    Hengel, Hartmut
    Wichmann, Ole
    Poethko-Mueller, Christina
    BMC INFECTIOUS DISEASES, 2017, 17
  • [36] Concerns on Vaccine against Varicella Caused by Varicella-Zoster Virus Infection
    Zeng, Wen-Bo
    Zhang, Fukun
    Cheng, Shuang
    Sun, Jin-yan
    Shen, Hongjie
    Luo, Min-Hua
    VIROLOGICA SINICA, 2021, 36 (01) : 159 - 162
  • [37] Fatal varicella due to the vaccine-strain varicella-zoster virus
    Leung, Jessica
    Siegel, Subhadra
    Jones, James F.
    Schulte, Cynthia
    Blog, Debra
    Schmid, D. Scott
    Bialek, Stephanie R.
    Marin, Mona
    HUMAN VACCINES & IMMUNOTHERAPEUTICS, 2014, 10 (01) : 146 - 149
  • [38] Seroprevalence of varicella-zoster virus (VZV) in the French population
    Debruyne, M
    Floret, D
    Khoshnood, B
    Emery, C
    Fagnani, F
    Lancon, F
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2004, 24 : S240 - S240
  • [39] Varicella-zoster vaccine virus: Evolution in action
    Cohen, Jeffrey I.
    PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2007, 104 (01) : 7 - 8
  • [40] Prevention of varicella and zoster by live attenuated VZV vaccine
    Hambleton, Sophie
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2008, 13 : 2696 - 2704